Core Scientific (CORZR) Debt to Equity (2021 - 2026)

Core Scientific has disclosed Debt to Equity across 6 years of filings, most recently posting -$1.57 for Q1 2026.

• Debt to Equity for Q1 2026 came in at -$1.57, up 54.64% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.57 (up 54.64% YoY), and the FY2025 annual result was -$1.1, up 3.29% from the prior year.
• Debt to Equity came in at -$1.57 for Q1 2026 at Core Scientific, down from -$1.1 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $2.06 in Q2 2022 to a low of -$3.47 in Q1 2025.
• The 5-year median for Debt to Equity is -$0.89 (2025), against an average of -$0.76.
• Across the five-year window, Debt to Equity soared 2168.09% in 2022 and tumbled 388830.33% in 2024, its largest moves.
• Core Scientific's Debt to Equity stood at $0.07 in 2022, then sank by 1682.89% to -$1.15 in 2023, then grew by 0.62% to -$1.14 in 2024, then grew by 3.29% to -$1.1 in 2025, then slumped by 42.94% to -$1.57 in 2026.
• The last three Debt to Equity figures came in at -$1.57 (Q1 2026), -$1.1 (Q4 2025), and -$0.85 (Q3 2025), per Business Quant data.